Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor
Authors:
- Mariana Rebolledo-BustilloMRMariana Rebolledo-Bustillo
- David Garcia-GomezDGDavid Garcia-Gomez
- Eliud Morales DávilaEDEliud Morales Dávila
- María Eugenia CastroMCMaría Eugenia Castro
- Norma A. CaballeroNCNorma A. Caballero
- Francisco J. MelendezFMFrancisco J. Melendez
- Victor M. Baizabal-AguirreVBVictor M. Baizabal-Aguirre
- Brenda L. Sanchez-GaytanBSBrenda L. Sanchez-Gaytan
- Jose Manuel Perez-AguilarJPJose Manuel Perez-Aguilar
Open Access
- 23 February 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (5) , 4393
Abstract
Modulation of the CXCL12–CXCR4 signaling axis is of the utmost importance due to its central involvement in several pathological disorders, including inflammatory diseases and cancer. Among the different currently available drugs that inhibit CXCR4 activation, motixafortide—a best-in-class antagonist of this GPCR receptor—has exhibited promising results in preclinical studies of pancreatic, breast, and lung cancers. However, detailed information on the interaction mechanism of motixafortide is still lacking. Here, we characterize the motixafortide/CXCR4 and CXCL12/CXCR4 protein complexes by using computational techniques including unbiased all-atom molecular dynamics simulations. Our microsecond-long simulations of the protein systems indicate that the agonist triggers changes associated with active-like GPCR conformations, while the antagonist favors inactive conformations of CXCR4. Detailed ligand–protein analysis indicates the importance of motixafortide’s six cationic residues, all of which established charge–charge interactions with acidic CXCR4 residues. Furthermore, two synthetic bulky chemical moieties of motixafortide work in tandem to restrict the conformations of important residues associated with CXCR4 activation. Our results not only elucidate the molecular mechanism by which motixafortide interacts with the CXCR4 receptor and stabilizes its inactive states, but also provide essential information to rationally design CXCR4 inhibitors that preserve the outstanding pharmacological features of motixafortide.Keywords
Funding Information
- PRODEP Academic Group BUAP-CA-263 (SEP, México) (929045, 1107336, 758730)
- CONACyT-Mexico (929045, 1107336, 758730)
- Coordinación de Investigación Científica, Universidad Michoacana de San Nicolás de Hidalgo (929045, 1107336, 758730)
This publication has 35 references indexed in Scilit:
- Molecular dynamics simulations and drug discoveryBMC Biology, 2011
- Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide AntagonistsScience, 2010
- Using VMD: An Introductory TutorialCurrent Protocols in Bioinformatics, 2008
- OPM: Orientations of Proteins in Membranes databaseBioinformatics, 2006
- Extending the treatment of backbone energetics in protein force fields: Limitations of gas‐phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulationsJournal of Computational Chemistry, 2004
- Modeller: Generation and Refinement of Homology-Based Protein Structure Models2003
- NAMD: a Parallel, Object-Oriented Molecular Dynamics ProgramThe International Journal of Supercomputer Applications and High Performance Computing, 1996
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Constant pressure molecular dynamics simulation: The Langevin piston methodThe Journal of Chemical Physics, 1995
- Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanesJournal of Computational Physics, 1977